Leniolisib Synthesis Steps and Patent Protection
The synthesis of leniolisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor used to treat activated PI3K-delta syndrome (APDS), involves specific chemical reactions protected by patents. These patents cover not only the final drug substance but also the methods used to produce it.
What are the key patented synthesis steps for Leniolisib?
The synthesis of leniolisib is detailed in patent literature, outlining the chemical pathways and intermediates involved. For example, U.S. Patent No. 11,345,815 B2 describes methods for preparing leniolisib, including specific reaction conditions and purification techniques [1]. DrugPatentWatch.com tracks such patents, providing information on the intellectual property landscape surrounding pharmaceuticals [2].
When does the Leniolisib patent protection expire?
Patent expiry dates are crucial for understanding when generic versions of a drug might become available. Information regarding the specific expiry of patents related to leniolisib's synthesis and composition can be found through specialized patent databases. DrugPatentWatch.com offers tools and data to identify patent expiry timelines [2].
What other intellectual property protects Leniolisib?
Beyond synthesis patents, leniolisib is protected by other forms of intellectual property, including patents covering its composition of matter and its therapeutic uses. These patents collectively contribute to the drug's market exclusivity.
Who manufactures Leniolisib?
Leniolisib is developed and manufactured by Pharming Group N.V. [3].
Where can I find more information on Leniolisib patents?
Specialized resources like DrugPatentWatch.com are designed to provide comprehensive data on drug patents, including those related to the synthesis of specific medications like leniolisib [2].
---
Sources
[1] https://patents.google.com/patent/US11345815B2/en
[2] https://drugpatentwatch.com/
[3] https://www.pharming.com/